AVI BIOPHARMA - Schweinegrippe-Profiteur

Global Biotech Investing - AVI BioPharma spekulativ aufspringen
12:02 07.07.09

Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten bei der Aktie von AVI BioPharma (Profil) mit einer kleinen spekulativen Position aufzuspringen.

Vor wenigen Tagen habe das Unternehmen einen Auftrag in Höhe von 5,1 Mio. USD von der US-Regierung erhalten. Bereits Anfang Mai sei mit der US-Defense-Threat-Reduction-Agency eine Vereinbarung zur Entwicklung mindestens eines Produktkandidaten gegen die Schweinegrippe getroffen worden. Nun sei dieser Deal endgültig fixiert worden.

Aktuell entwickle AVI BioPharma in Phase I die beiden Wirkstoffe AVI-6002 und AVI-6003 zur Behandlung von Ebola und des Marburg-Virus. Zusätzlich treibe das Unternehmen - teilweise auch in Zusammenarbeit mit Partnerunternehmen - Forschungsreihen im Bereich von Herz-/Kreislauferkrankungen und bei DMD, einer bislang tödlich verlaufenden Muskelerkrankung, voran. Diese Produktpipeline sei zwar spannend, da sich aber alles noch in einer frühen Forschungsphase befinde werde es noch Jahre dauern, bis das Unternehmen damit Geld verdiene. Deshalb seien unerwartete Aufträge wie aktuell seitens der US-Regierung ein Segen für AVI BioPharma. Eines sei sicher: Bringe das Unternehmen nur einen seiner Produktkandidaten zur Marktreife, würde dies einen Durchbruch für die nur USD 120 Mio. schwere Gesellschaft bedeuten.

Branchenexperten seien vom mittelfristigen Potenzial des Unternehmens komplett überzeugt. Neben dem Regierungsauftrag würden der Aktie derzeit auch durch die Aufnahme in den Russell 3000 Index Beine gemacht.

Die Experten von "Global Biotech Investing" empfehlen bei der Aktie von AVI BioPharma mit einer kleinen spekulativen Position auf die laufende Rally aufzuspringen. (Ausgabe 13 vom 06.07.2009) (07.07.2009/ac/a/a)


Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

Quelle: Aktiencheck

heute und das Volumen hat auch angezogen. Keine News erkennbar.

Schweinegrippe USA planen Massenimpfung gegen Schweinegrippe-Virus

Im Kampf gegen die Schweinegrippe planen die USA im Herbst eine Massenimpfung. Die Gesundheitsbehörden wollen bis Mitte Oktober 100 Millionen Einheiten eines Impfstoffs zur Verfügung stellen.
Die Impfaktion soll sich auf Schulkinder, Schwangere sowie chronisch Kranke und Krankenhaus-Beschäftigte konzentrieren, die als besonders gefährdet durch das H1N1-Virus gelten.

Bisherigen Schätzungen zufolge sollen bereits eine Million Amerikaner an Schweinegrippe erkrankt sein – 170 starben, dies berichtete die „Washington Post“.

Bei der Weltgesundheitsorganisation (WHO) sind bislang rund 35 000 Erkrankungen in den USA registriert, Mediziner gehen aber weltweit von einer sehr großen Dunkelziffer aus. Experten warnten auf einem Gesundheitsgipfel vor der Einschätzung, dass die Pandemie bereits vorüber sei.

Vor einem Beginn der Massenimpfungen müsse aber zunächst garantiert werden, dass der Impfstoff sicher und effektiv sei – entsprechende Tests seien für August geplant, berichtete die „New York Times“. Da es aber vermutlich nicht genügend Impfstoff für die gesamte Bevölkerung gebe, müsse man sich zunächst auf Risikogruppen beschränken.

Die Bundesregierung will in der kommenden Woche festlegen, welche Bevölkerungsgruppen in Deutschland gegen die Schweinegrippegeimpft werden sollten.

„Wir müssen entscheiden, wer zu den Risikogruppen gehört“, sagte Bundesgesundheitsministerin Ulla Schmidt (SPD) dem Hörfunksender Hit-Radio Antenne Niedersachsen.

Dazu dürften die Beschäftigten im Gesundheitswesen, aber auch junge Menschen mit Grunderkrankungen gehören.

Für diese Gruppen solle eine Impfempfehlung ausgesprochen werden, so die Gesundheitsministerin.

Die Bestelloptionen für Grippemittel reichten aus, um jeden Deutschen zweimal zu impfen. Unklar sei noch, ob bei älteren Menschen eine Impfung sinnvoll sei, sagte Schmidt. In dieser Altersgruppe gebe es kaum Erkrankungen. Möglicherweise reiche hier der normale saisonale Grippeimpfstoff aus.

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

und das Volumen stimmt auch.

neues 52 Wochen Hoch, gutes Volumen und die zwei Dollar werden gekratzt.

schöner Anstieg

The agreement has a one-year term, with an option to extend for additional years, and will provide approximately $1.2 million in support to AVI over the initial term for advancement of research, regulatory efforts and clinical trial recruitment.

AVI is currently conducting a dose-finding clinical trial evaluating the systemic delivery of AVI-4658. This is an open label, 12 week safety trial, which includes measures of drug efficacy and pharmacokinetics, being conducted in London, UK, at the UCL Institute of Child Health/Great Ormond Street Hospital NHS Trust facilities and at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

AVI-4658 is designed to skip exon 51 of the dystrophin gene, allowing for restoration of the reading frame in the mRNA sequence. By skipping this exon, a truncated, yet potentially functional form of the dystrophin protein is produced, which could ameliorate the disease process and possibly prolong and improve the quality of life of these patients. Results from a Phase 1 proof-of-concept trial showed that injection of the drug into the muscles of a series of DMD boys successfully induced dystrophin production in a dose-responsive manner. Further, the drug was well tolerated, with no significant drug-related adverse events detected. The clinical trial was conducted in collaboration with the MDEX Consortium in London, UK. AVI is also developing AVI-5038, a new candidate drug based on second-generation PPMO chemistry and designed to skip exon 50. The preclinical work for AVI-5038 is funded in part by Charlie's Fund. The Company is currently working to advance this new drug candidate into clinical trials under an investigational new drug application (IND) in the United States and an investigational medicinal product dossier (IMPD) in Europe.

About Duchenne Muscular Dystrophy (DMD)

DMD is the most common fatal genetic disorder to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne Muscular Dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children before age six. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time in decades, there are promising therapies in or moving into development.

About Action Duchenne

Action Duchenne (formally Parent Project UK) was set up by Duchenne families in 2001 to promote new research for a cure for Duchenne. The charity has a strong record in funding research and has to date funded 9 major projects costing over £1m and has been a leading partner in the £1.6m DoH MDEX project. These projects have enabled much needed early work to be completed on exon skipping and other therapeutic approaches.

Action Duchenne holds an international conference every year to bring together researchers and families to exchange new research developments and provide a vital meeting venue for scientists.

In 2005 Action Duchenne launched the Duchenne Registry, the first National Duchenne database that holds gene information of people living with Duchenne and can be used to speed up the recruitment of patients for clinical trials. In 2006 Action Duchenne launched a comprehensive learning and behaviour toolkit for use by parents and education professionals. For more information please visit: www.actionduchenne.org

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
(541) 224-2575
Investorrelations@avibio.com

Action Duchenne Contacts:
Nick Catlin
CEO
Action Duchenne
+44 (0) 20 8556 9955
Email: nick@actionduchenne.orgAndreina West
PR Artistry
+44 (0) 1491 639500
email: Andreina@pra-ltd.co.uk

die Aktie läuft gut.

ohne erkennbare News.

ist das evtl. der Grund für den Anstieg ?

dabei?

AVI BioPharma Announces Second Quarter 2009 Financial Results Conference Call
For Immediate Release
CORVALLIS, OR — August 3, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report second quarter 2009 financial results on Monday, August 10, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

Individuals interested in listening to the live conference call may do so by dialing 800-967-7135 toll free within the United States and Canada, or 719-457-2603 for international callers.

A replay of the call will be available by dialing 888-203-1112 toll free within the U.S. and Canada or 719-457-0820 for international callers. The passcode for the replay is 4026242. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

www.nasdaq.com//aspxcontent/...;cdtime=08%2F10%2F2009+8%3A00AM

quotes.nasdaq.com/asp/...ote.asp?symbol=AVII&selected=AVII

und starker Anstieg heute. News bisher nicht erkennbar.

der Anstig ist erfreulich, die Frage ist nur, ob es sich um einen kurzen Ausbruch handelt.

kommt bei so einem Volumen die News noch. Da haben vermutlich Leute gekauft die vorher etwas wußten, anders kann ich es mir nicht erklären.

und Novavax auch.

gestern. Fängt ja in den USA gut an.

http://www.marketwatch.com/investing/stock/AVII?siteid=mktw

mit Novavax. Die haben positive Phase II Ergebnisse.

und dann noch so ein schöner Anstieg.

www.marketwatch.com/story/...-investment-conference-2009-09-02

handelt ihr die aktie?

in NY, nur dort ist der Markt entsprechend liquide.

und auch das Volumen hat zugelegt.

quotes.nasdaq.com/asp/...ote.asp?symbol=AVII&selected=AVII